🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

IDEXX Labs Q3 earnings top estimates, revenue falls short

EditorRachael Rajan
Published 10/31/2024, 06:55 AM
© Reuters.
IDXX
-

WESTBROOK, Maine - IDEXX Laboratories, Inc. (NASDAQ: IDXX) reported better-than-expected third quarter earnings on Thursday, though revenue came in slightly below analyst forecasts. The pet healthcare company also lowered its full-year revenue guidance.

IDEXX shares rose 1.2% in early trading following the earnings release.

IDEXX posted adjusted earnings per share of $2.79 for Q3, surpassing the analyst consensus of $2.68. Revenue grew 6.6% year-over-year to $975.5 million, but fell short of estimates calling for $979.98 million.

The company's Companion Animal Group segment, which includes veterinary diagnostic products and services, saw revenue increase 6.5% to $892 million. Water segment revenue rose 12.9% to $50.2 million.

"IDEXX teams continued their strong execution in the third quarter as demonstrated by solid net customer gains, continued growth in our premium IDEXX VetLab instrument installed base, and nearly 700 pre-orders of IDEXX inVue Dx Cellular Analyzer, which will begin shipping later in the fourth quarter," said Jay Mazelsky, President and CEO.

For the full year 2024, IDEXX lowered its revenue guidance to a range of $3.865-$3.89 billion, down from its previous outlook of $3.885-$3.945 billion and below the consensus of $3.918 billion. The company narrowed its 2024 EPS forecast to $10.37-$10.53, maintaining the midpoint of its prior range but below analyst expectations of $10.81.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.